3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
AbbVie's dividend payout has more than tripled over the past decade, and it could soar much further in the decade ahead. Bristol Myers Squibb offers a juicy 4.7% dividend yield at recent prices.
Here's Why AbbVie (ABBV) Fell More Than Broader Market
In the latest trading session, AbbVie (ABBV) closed at $169.80, marking a -0.12% move from the previous day.
Is Johnson & Johnson Stock A Better Pick Over AbbVie?
We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer AbbVie (NYSE: ABBV). AbbVie ABBV trades at a higher valuation of 5.5x trailing ...
Passive Income Perfection: 7 Dividend Stocks to Generate $50,000 Per Year
The topic of passive income is popular these days. Investors, consumers, and many other individuals are curious about any method that can produce income without work.
2 Strong Dividend Buys And 2 Sells For Q2 2024
I present you our framework for buying and selling dividend stocks. It follows our simple motto of buy low, sell high, get paid to wait. Here are 2 brilliant buys and 2 smart sells for Q2 2024.
The 3 Best Stocks to Buy in April 2024
The big money might be feeling a bit queasy about overexposure to risk-on assets, presenting a framework to follow regarding the best stocks to buy in April. As I've mentioned many times before, te...
3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade
Now that it's focused on just medical technology and pharmaceuticals, Johnson & Johnson's pace of annual dividend raises could accelerate. Medtronic is the largest publicly traded medical device ma...
AbbVie acquisition signals confidence in small-cap biotech sector's growth potential
AbbVie Inc (NYSE:ABBV)'s approximately $137.5 million acquisition of Landos Biopharma is a strategic move by the pharmaceutical research and development firm which has reiterated the potential of n...
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.
AbbVie (ABBV) Advances While Market Declines: Some Information for Investors
AbbVie (ABBV) closed at $178.53 in the latest trading session, marking a +0.04% move from the prior day.
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
AbbVie to buy Landos to expand pipeline of immunity-related illnesses
AbbVie said on Monday it would acquire drug developer Landos Biopharma for up to $212 million as the Humira-maker aims to expand its pipeline of medicines to treat immune system-related illnesses.
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie
Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease. Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and t...
AbbVie's New ‘Biological Missile' Ovarian Cancer Treatment Gets Full FDA Approval
The Food and Drug Administration said Friday it granted full approval to AbbVie and ImmunoGen's cancer drug mirvetuximab-soravtansine-gynx, or Elahere, part of a new class of cancer treatments cons...
Related Companies